DNL104 or placebo
Sponsors
Denali Therapeutics
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Unknown Phase
A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of DNL104 in Healthy Subjects
Active, not recruitingNL-OMON42834
Start: 2016-09-03Target: 48Updated: 2025-09-08
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of DNL104 in Healthy Subjects
Active, not recruitingNL-OMON45306
Start: 2017-01-10Target: 30Updated: 2025-09-08